fsa compounded tirzepatide With B6 (Pyridoxine) Compounded Tirzepatide

doi: 10.1016/j.isci.2019.100772 463 ChenDJinDHuangSWuJXuMLiuTet al

According to the SmPC, no dose adjustment is required for patients with mild to moderate renal or hepatic impairment, as pharmacokinetic changes across these populations are not clinically relevant, but use is not recommended in cases of severe renal or hepatic impairment due to limited experience

Adjusting Dosage : Transitioning from semaglutide to tirzepatide may involve titrating doses to ensure seamless continuity in weight loss program and prevent severe side effects

Earlier studies demonstrated that the incretin effect of GIP was severely impaired in patients with uncontrolled T2DM (57)